Shares of Amgen Inc. fell 1.0% in premarket trading Monday after the biotechnology company said it agreed to buy Celgene Corp.’s psoriasis treatment Otezla for $13.4 billion in cash.
Bristol-Myers Squibb Co. said the previously announced decision to Otezla was part of the regulatory approval process for the pending acquisition of Celgene. Shares of Celgene surged 3.7% in premarket trading and Bristol-Myers Squibb Co. shot up 5.2%. Amgen said the deal will immediately add to adjusted earnings per share, and will not interrupt the deployment of its capital allocation priorities.
“The acquisition of Otezla offers a unique opportunity for Amgen to provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits squarely within our portfolio and complements our Enbrel(R) and AMGEVITA(R) brands,” said Amgen Chief Executive Robert Bradway.
Amgen’s stock has gained 2.3% year to date while the Dow Jones Industrial Average rallied 9.9%.
By Tomi Kilgore
Source: MarketWatch
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.